Condition
Type 1 Interferonopathies
Total Trials
3
Recruiting
1
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 1 (2)
Trial Status
Not Yet Recruiting1
Active Not Recruiting1
Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07837986Not ApplicableNot Yet Recruiting
Investigation of Type I Interferon Excess in Patients With Systemic Autoimmune Diseases and Genetic Type I Interferonopathies
NCT06878365Phase 1Active Not RecruitingPrimary
A Study to Test How Well BI 3000202 is Tolerated by People With Type 1 Interferonopathies
NCT07364513Phase 1RecruitingPrimary
Phase 1b Safety Study of IMSB301 in Type 1 Interferonopathies
Showing all 3 trials